Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Device Fees Uplift Next Year As MHRA Begins Consultation

Agency sets long-term goal of self sufficiency

Executive Summary

UK device industry stakeholders will have until 23 November to respond to the UK MHRA’s newly-proposed fee increases, which the agency says will enable it to secure full cost recovery of the services it provides.

You may also be interested in...



UK MHRA Notes Concern Over Medtech’s Mid-2023 Deadline – But Still No Draft Law Progress

The One Agency initiative, patient safety, methods of funding and recruitment needs were pressing discussion themes during the MHRA’s April 2022 board meeting held in public.

MHRA Chairman Lightfoot Ready To Lead Post-EU Agenda For UK Devices

The UK devices regulator will prioritize innovation, global best practice and enhanced patient safety and the patient voice, MHRA board chairman Stephen Lightfoot said during the ABHI’s spring regulatory conference. New fees for industry are also on the cards.

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel